Welcome to our dedicated page for Jaguar Health news (Ticker: $JAGX), a resource for investors and traders seeking the latest updates and insights on Jaguar Health stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Jaguar Health's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Jaguar Health's position in the market.
Jaguar Health, Inc. (NASDAQ: JAGX) will hold an investor webcast on May 14, 2024, to discuss Q1 2024 financials and corporate updates. The company plans to file its Earnings Report on Form 10-Q for the quarter ended March 31, 2024.
Jaguar Health's prescription drug crofelemer, approved by the FDA for chemotherapy-induced diarrhea in dogs, is now being investigated for the treatment of general diarrhea in dogs. The company aims to address the unmet need for FDA-approved anti-secretory agents for canine diarrhea.
Jaguar Health, Inc. announced that its subsidiary Napo Pharmaceuticals is sponsoring a Pediatric Gastroenterology Conference in Abu Dhabi and a panel discussion on Microvillus Inclusion Disease. The company's drug crofelemer has Orphan Drug Designation for MVID and short bowel syndrome (SBS). Proof-of-concept studies for these diseases are planned for 2024. The FDA activated Napo's IND application for a phase 2 trial of crofelemer for pediatric MVID patients, with results expected in 2024. MVID is a severe infantile disease with no approved treatments. Leading experts in MVID treatment will participate in the panel discussion.